Read by QxMD icon Read

Suerie Moon

Suerie Moon, Jennifer Leigh, Liana Woskie, Francesco Checchi, Victor Dzau, Mosoka Fallah, Gabrielle Fitzgerald, Laurie Garrett, Lawrence Gostin, David L Heymann, Rebecca Katz, Ilona Kickbusch, J Stephen Morrison, Peter Piot, Peter Sands, Devi Sridhar, Ashish K Jha
No abstract text is available yet for this article.
January 23, 2017: BMJ: British Medical Journal
Suerie Moon
One of the few issues uniting U.S. voters in the 2016 election was outrage over the high prices of medicines. From the quadrupling of EpiPen prices to $1,000-per-pill hepatitis C treatments, from six-digit pricing of cancer drugs to the 55-fold price increase on a 62-year-old toxoplasmosis drug,..
February 9, 2017: New England Journal of Medicine
Laura Diaz Anadon, Gabriel Chan, Alicia G Harley, Kira Matus, Suerie Moon, Sharmila L Murthy, William C Clark
This paper presents insights and action proposals to better harness technological innovation for sustainable development. We begin with three key insights from scholarship and practice. First, technological innovation processes do not follow a set sequence but rather emerge from complex adaptive systems involving many actors and institutions operating simultaneously from local to global scales. Barriers arise at all stages of innovation, from the invention of a technology through its selection, production, adaptation, adoption, and retirement...
August 30, 2016: Proceedings of the National Academy of Sciences of the United States of America
Lawrence O Gostin, Oyewale Tomori, Suwit Wibulpolprasert, Ashish K Jha, Julio Frenk, Suerie Moon, Joy Phumaphi, Peter Piot, Barbara Stocking, Victor J Dzau, Gabriel M Leung
Lawrence Gostin and colleagues offer a set of priorities for global health preparedness and response for future infectious disease threats.
May 2016: PLoS Medicine
Devi Sridhar, Ilona Kickbusch, Suerie Moon, Victor Dzau, David Heymann, Ashish K Jha, Jorge Saavendra, Barbara Stocking, Liana Woskie, Peter Piot
No abstract text is available yet for this article.
May 18, 2016: BMJ: British Medical Journal
Suerie Moon, Devi Sridhar, Muhammad A Pate, Ashish K Jha, Chelsea Clinton, Sophie Delaunay, Valnora Edwin, Mosoka Fallah, David P Fidler, Laurie Garrett, Eric Goosby, Lawrence O Gostin, David L Heymann, Kelley Lee, Gabriel M Leung, J Stephen Morrison, Jorge Saavedra, Marcel Tanner, Jennifer A Leigh, Benjamin Hawkins, Liana R Woskie, Peter Piot
No abstract text is available yet for this article.
November 28, 2015: Lancet
Suerie Moon
What are the human rights responsibilities of pharmaceutical companies with regard to access to medicines? The state-based international human rights framework has long struggled with the issue of the human rights obligations of non-state actors, a question sharpened by economic globalization and the concomitant growing power of private for-profit actors ("business"). In 2011, after a six-year development process, the UN Human Rights Council unanimously endorsed the Guiding Principles advanced by the UN Secretary General's Special Representative on Business and Human Rights, John Ruggie...
2013: Health and Human Rights
Ole Petter Ottersen, Jashodhara Dasgupta, Chantal Blouin, Paulo Buss, Virasakdi Chongsuvivatwong, Julio Frenk, Sakiko Fukuda-Parr, Bience P Gawanas, Rita Giacaman, John Gyapong, Jennifer Leaning, Michael Marmot, Desmond McNeill, Gertrude I Mongella, Nkosana Moyo, Sigrun Møgedal, Ayanda Ntsaluba, Gorik Ooms, Espen Bjertness, Ann Louise Lie, Suerie Moon, Sidsel Roalkvam, Kristin I Sandberg, Inger B Scheel
No abstract text is available yet for this article.
February 15, 2014: Lancet
Suerie Moon
Recent global debates on the research and development (R&D) of health technologies, such as drugs, diagnostics and vaccines, can be seen as a microcosm of discussions on the role of the World Health Organization (WHO) in the global health system more broadly. The global R&D system has come under heightened scrutiny with the publication of a 2012 report by the WHO Consultative Expert Working Group on Research and Development (CEWG), which made a number of recommendations to more equitably meet global health needs...
February 2014: Public Health
Julio Frenk, Octavio Gómez-Dantés, Suerie Moon
No abstract text is available yet for this article.
January 4, 2014: Lancet
Julio Frenk, Suerie Moon
Global health is at the threshold of a new era. Few times in history has the world faced challenges as complex as those now posed by a trio of threats: first, the unfinished agenda of infections, undernutrition, and reproductive health problems; second, the rising global burden of noncommunicable..
March 7, 2013: New England Journal of Medicine
Suerie Moon, Jorge Bermudez, Ellen 't Hoen
No abstract text is available yet for this article.
2012: PLoS Medicine
Suerie Moon, Elodie Jambert, Michelle Childs, Tido von Schoen-Angerer
BACKGROUND: Tiered pricing - the concept of selling drugs and vaccines in developing countries at prices systematically lower than in industrialized countries - has received widespread support from industry, policymakers, civil society, and academics as a way to improve access to medicines for the poor. We carried out case studies based on a review of international drug price developments for antiretrovirals, artemisinin combination therapies, drug-resistant tuberculosis medicines, liposomal amphotericin B (for visceral leishmaniasis), and pneumococcal vaccines...
2011: Globalization and Health
Ellen 't Hoen, Jonathan Berger, Alexandra Calmy, Suerie Moon
Since 2000, access to antiretroviral drugs to treat HIV infection has dramatically increased to reach more than five million people in developing countries. Essential to this achievement was the dramatic reduction in antiretroviral prices, a result of global political mobilization that cleared the way for competitive production of generic versions of widely patented medicines.Global trade rules agreed upon in 1994 required many developing countries to begin offering patents on medicines for the first time. Government and civil society reaction to expected increases in drug prices precipitated a series of events challenging these rules, culminating in the 2001 World Trade Organization's Doha Declaration on the Agreement on Trade-Related Aspects of Intellectual Property Rights and Public Health...
2011: Journal of the International AIDS Society
Brenda Waning, Ellen Diedrichsen, Elodie Jambert, Till Bärnighausen, Yun Li, Mieke Pouw, Suerie Moon
BACKGROUND: Important advances in the development and production of quality-certified pediatric antiretroviral (ARV) formulations have recently been made despite significant market disincentives for manufacturers. This progress resulted from lobbying and innovative interventions from HIV/AIDS activists, civil society organizations, and international organizations. Research on uptake and dispersion of these improved products across countries and international organizations has not been conducted but is needed to inform next steps towards improving child health...
2010: BMC Pediatrics
Brenda Waning, Ellen Diedrichsen, Suerie Moon
BACKGROUND: Indian manufacturers of generic antiretroviral (ARV) medicines facilitated the rapid scale up of HIV/AIDS treatment in developing countries though provision of low-priced, quality-assured medicines. The legal framework in India that facilitated such production, however, is changing with implementation of the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights, and intellectual property measures being discussed in regional and bilateral free trade agreement negotiations...
2010: Journal of the International AIDS Society
Brenda Waning, Margaret Kyle, Ellen Diedrichsen, Lyne Soucy, Jenny Hochstadt, Till Bärnighausen, Suerie Moon
BACKGROUND: Universal access to antiretroviral therapy (ART) in low- and middle-income countries faces numerous challenges: increasing numbers of people needing ART, new guidelines recommending more expensive antiretroviral (ARV) medicines, limited financing, and few fixed-dose combination (FDC) products. Global initiatives aim to promote efficient global ARV markets, yet little is known about market dynamics and the impact of global policy interventions. METHODS: We utilize several data sources, including 12,958 donor-funded, adult first-line ARV purchase transactions, to describe the market from 2002-2008...
2010: Globalization and Health
Suerie Moon, Nicole A Szlezák, Catherine M Michaud, Dean T Jamison, Gerald T Keusch, William C Clark, Barry R Bloom
No abstract text is available yet for this article.
January 2010: PLoS Medicine
Gerald T Keusch, Wen L Kilama, Suerie Moon, Nicole A Szlezák, Catherine M Michaud
No abstract text is available yet for this article.
January 2010: PLoS Medicine
Nicole A Szlezák, Barry R Bloom, Dean T Jamison, Gerald T Keusch, Catherine M Michaud, Suerie Moon, William C Clark
In the first in a series of four articles highlighting the changing nature of global health institutions, Nicole Szlezák and colleagues outline the origin and aim of the series.
January 2010: PLoS Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"